Get the Stockscreener App
0.00
100.00%
-0.048
After Hours:
.05
0.05
+
Io Biotech Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
See More
Previous Close:
$0.048
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$3.45M
Revenue:
-
Net Income/Loss:
$-88.35M
P/E Ratio:
0.00
EPS:
-1.3391
Net Cash Flow:
$-81.07M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$2.08
Io Biotech Inc Stock (IOBT) Company Profile
Name
Io Biotech Inc
Sector
Industry
Phone
(457) 070-2980
Address
OLE MAALOES VEH 3, COPENHAGEN
Compare IOBT vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOBT
Io Biotech Inc
|
0.00 | 3.45M | 0 | -88.35M | -81.07M | -1.3391 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Io Biotech Inc Stock (IOBT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-08-26 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-30-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-30-25 | Downgrade | TD Cowen | Buy → Hold |
Io Biotech Inc Stock (IOBT) Latest News
Metastatic Melanoma Therapeutics Market Study Highlights How Industry Demand Is Evolving - openPR.com
Silicone Tubing for Biotech Market Growth to 2035 Driven by Single-Use SystemsNews and Statistics - IndexBox
Layoff Tracker: Kolon TissueGene cuts 37 US staffers after Phase 3 fail - BioSpace
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy - finance.yahoo.com
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer - GlobeNewswire
Ascentage Pharma appoints Miyara, Ziegler to lead global expansion - scanx.trade
All You Need to Know About Data IO (DAIO) Rating Upgrade to Buy - Yahoo Finance
FDA scientists question Capricor data; Legend CEO steps down - BioPharma Dive
IO Biotech, Inc. Revenue Breakdown – OTC:IOBTQ - TradingView
Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire - Endpoints News
Elevara Medicines appoints biotech veteran as CEO - The Pharma Letter
Elevara Medicines Appoints Biotech Veteran as CEO - markets.businessinsider.com
Price to sales forward of IO Biotech, Inc. – OTC:IOBTQ - TradingView
Price to earnings forward of IO Biotech, Inc. – OTC:IOBTQ - TradingView
Enterprise value to revenue forward of IO Biotech, Inc. – OTC:IOBTQ - TradingView
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.18% - Investing.com
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years - nature.com
Cancer Vaccines Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca - Barchart.com
Cancer Vaccines Market Unlocking New Revenue Opportunities - openPR.com
IO Biotech Inc (IOBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IO Biotech, Inc. Actuals & Estimates (OTC:IOBTQ) - TradingView
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy - Yahoo Finance
IO Biotech Inc (IOBT) Institutional Confidence - TradingKey
IO Biotech Inc (IOBT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IO Biotech Inc (IOBT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IO Biotech Inc (IOBT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IO Biotech Inc (IOBT) Valuation: PE, PB & Fair Value Analysis - TradingKey
IO Biotech Inc (IOBT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IO Biotech Inc (IOBT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IO Biotech Inc (IOBT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher - Yahoo Finance
IO Biotech (IOBT) common stock removed from Nasdaq in voluntary withdrawal - Stock Titan
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Bears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' Now - Yahoo Finance
Major IO Biotech (IOBT) shareholder updates 27.4% stake as company enters Chapter 7 - Stock Titan
IOBTQ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IO Biotech Holds Steady at $0.05: Navigating Extremely Low Valuation TerritoryDay Trade Opportunities - dars.gov.et
IO Biotech (IOBT) Holds Steady at $0.05 as Key Support and Resistance ConvergeTrend Continuation Trade - The Legal Advocate
IO Biotech Q3 2025 Earnings: EPS Beat of 60.67% Surprise, but No Revenue from Pre-Commercial PipelineEstimate Revision Count - The Legal Advocate
Io Biotech Inc Stock (IOBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):